Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease

International Immunopharmacology

Volumn 8, Issue 6, 2008, Pages 836-844

  Melgar, Silvia ^a   Karlsson, Lisa ^a   Rehnström, Erika ^a   Karlsson, Agneta ^a   Utkovic, Helena ^a   Jansson, Liselotte ^a   Michaëlsson, Erik ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Acute and chronic colitis; Anti CD3; Anti IL 12p40; CsA; DSS; MTX

Indexed keywords

CD3 ANTIBODY; CYCLOSPORIN A; CYTOKINE; DEXTRAN SULFATE; INTERLEUKIN 12P40; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; COLITIS; DRUG EFFICACY; ENTERITIS; FEMALE; HISTOLOGY; INFLAMMATION; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL;

ACUTE DISEASE; ANIMALS; ANTIBODIES; ANTIGENS, CD3; CHRONIC DISEASE; COLITIS; CYCLOSPORINE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-12 SUBUNIT P40; METHOTREXATE; MICE; MICE, INBRED C57BL;

EID: 43049135132     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.036     Document Type: Article

References (38)

1. Byrne F.R., and Viney J.L. Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Dev 9 (2006) 207-217
2. Jakobovits S.L., and Travis S.P.L. Management of acute severe colitis. Br Med Bull 75-76 (2006) 131-144
3. Jarnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlen P., Granno C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. [see comment]. Gastroenterology 128 (2005) 1805-1811
4. Kullberg M.C., Rothfuchs A.G., Jankovic D., Caspar P., Wynn T.A., Gorelick P.L., et al. Helicobacter hepaticus-induced colitis in interleukin-10-deficient mice: cytokine requirements for the induction and maintenance of intestinal inflammation. Infect Immun 69 (2001) 4232-4241
5. Totsuka T., Kanai T., Uraushihara K., Iiyama R., Yamazaki M., Akiba H., et al. Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 284 (2003) G595-G603
6. Scheinin T., Butler D.M., Salway F., Scallon B., and Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133 (2003) 38-43
7. Powrie F., Leach M.W., Mauze S., Menon S., Caddle L.B., and Coffman R.L. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1 (1994) 553-562
8. Danese S., Semeraro S., Armuzzi A., Papa A., and Gasbarrini A. Biological therapies for inflammatory bowel disease: research drives clinics. MinRev Med Chem 6 (2006) 771-784
9. Bjursten M., Bland P.W., Willén R., and Hultgren Hornquist E. Long-term treatment with anti-a4 integrin antibodies aggravates colitis in Gai2-deficient mice. Eur J Immunol 35 (2005) 2274-2283
10. Melgar S., Karlsson A., and Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 288 (2005) G1328-G1338
11. Modigliani R., Mary J.Y., Simon J.F., Cortot A., Soule J.C., Gendre J.P., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Gastroenterology 98 (1990) 811-818
12. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98 (1990) 694-702
13. Melgar S., Drmotova M., Rehnstrom E., Jansson L., and Michaelsson E. Local production of chemokines and prostaglandin E2 in the acute, chronic and recovery phase of murine experimental colitis. Cytokine 35 (2006) 275-283
14. Larsson A.E., Melgar S., Rehnstrom E., Michaelsson E., Svensson L., Hockings P., et al. Magnetic resonance imaging of experimental mouse colitis and association with inflammatory activity. Inflamm Bowel Dis 12 (2006) 478-485
15. Murthy S.N., Cooper H.S., Shim H., Shah R.S., Ibrahim S.A., and Sedergran D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38 (1993) 1722-1734
16. Campbell S., Travis S., and Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 17 (2005) 79-84
17. Lange F., Bajtner E., Rintisch C., Nandakumar K.S., Sack U., and Holmdahl R. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis 64 (2005) 599-605
18. Fraser A.G. Methotrexate: first-line or second-line immunomodulator?. Eur J Gastroenterol Hepatol 15 (2003) 225-231
19. Kincaid R.L., Takayama H., Billingsley M.L., and Sitkovsky M.V. Differential expression of calmodulin-binding proteins in B, T lymphocytes and thymocytes. Nature 330 (1987) 176-178
20. Harrison C.A., Bastan R., Peirce M.J., Munday M.R., and Peachell P.T. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol 150 (2007) 509-518
21. Kountouras J., Zavos C., and Chatzopoulos D. Immunomodulatory benefits of cyclosporine A in inflammatory bowel disease. J Cell Mol Med 8 (2004) 317-328
22. Lee M., and Park J. Regulation of NFAT activation: a potential therapeutic target for immunosuppression. Mol Cells 22 (2006) 1-7
23. Soriano-Izquierdo A., Gironella M., Massaguer A., Salas A., Gil F., Pique J.M., et al. Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis. Inflamm Bowel Dis 10 (2004) 789-800
24. Ranganathan P., and McLeod H.L. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 54 (2006) 1366-1377
25. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
26. Fuss I.J., Marth T., Neurath M.F., Pearlstein G.R., Jain A., and Strober W. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. [see comment]. Gastroenterology 117 (1999) 1078-1088
27. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
28. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
29. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F., et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 12 (2006) 9-15
30. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
31. Uhlig H.H., McKenzie B.S., Hue S., Thompson C., Joyce-Shaikh B., Stepankova R., et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. [see comment]. Immunity 25 (2006) 309-318
32. Scheerens H., Hessel E., de Waal-Malefyt R., Leach M.W., and Rennick D. Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Eur J Immunol 31 (2001) 1465-1474
33. Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol 17 (2005) 632-637
34. Chatenoud L., Thervet E., Primo J., and Bach J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91 (1994) 123-127
35. Steffens S., Burger F., Pelli G., Dean Y., Elson G., Kosco-Vilbois M., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 114 (2006) 1977-1984
36. Ochi H., Abraham M., Ishikawa H., Frenkel D., Yang K., Basso A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25-LAP+ T cells. Nat Med 12 (2006) 627-635
37. Belghith M., Bluestone J.A., Barriot S., Megret J., Bach J.F., and Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9 (2003) 1202-1208
38. Ferran C., Dy M., Sheehan K., Merite S., Schreiber R., Landais P., et al. Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release. Clin Exp Immunol 86 (1991) 537-543